"The Mission of University Gastroenterology (UGI) is to provide comprehensive gastrointestinal care in a patient friendly setting. By using the newest medical technology and implementing the highest clinical standards, the physicians of UGI are dedicated to providing treatment for a wide array of gastrointestinal and liver diseases. For over 30 years, University Gastroenterology has been privileged to serve the communities of Southern New England. We appreciate the trust and confidence of our patients and referring physicians and look forward to your visit."

During the past decade, University Gastroenterology conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 22 clinical trials were completed, i.e. on average, 91.7% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 10 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Gastroenterology" #1 sponsor was "Gilead Sciences" with 22 trials, followed by "Bristol-Myers Squibb" with 8 trials sponsored, "Celgene" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Eli Lilly and Company" with 3 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Gastroenterology" #1 collaborator was "Novo Nordisk A/S" with 2 trials as a collaborator, "Dr. Naga Chalasani, MD, Indiana University" with 1 trials as a collaborator, "Dr. Stephen A. Harrison, MD, Brooke Army Medical Center" with 1 trials as a collaborator and "Sucampo Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "University Gastroenterology" are "Hepatitis C" (6 trials), "Nonalcoholic Steatohepatitis" (6 trials), "Chronic Hepatitis C" (4 trials), "Crohn's Disease" (4 trials) and "Hepatitis C, Chronic" (4 trials). Many other conditions were trialed in "University Gastroenterology" in a lesser frequency.

Most popular intervention types in "University Gastroenterology" are "Drug" (40 trials), "Biological" (6 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "RBV" (6 trials), "SOF" (5 trials), "Daclatasvir" (3 trials) and "Ribavirin" (3 trials). Other intervention names were less common.

The vast majority of trials in "University Gastroenterology" are 45 trials for "All" genders.

Currently, there are NaN active trials in "University Gastroenterology". undefined are not yet recruiting, 7 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in University Gastroenterology, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in University Gastroenterology, 0 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".